What is the difference between Fulphila and Neulasta?
Medically reviewed by Drugs.com. Last updated on Sep 19, 2019.
A biosimilar is a biological product that is highly similar to a biologic already approved by the FDA (known as the reference product) and has no clinically meaningful differences in terms of safety, purity and potency from the reference product. Biosimilars can provide cost effective treatment options to already approved biologics.
Fulphila and Neulasta are both used in cancer patients to boost the production of infection-fighting white blood cells and to help prevent neutropenia caused by chemotherapy.
More information: What Are Biosimilars? Top Facts You May Not Know
Related Medical Questions
- Why do you take Claritin with Neulasta?
- When can I remove the Neulasta Onpro?
- What does cbqv stand for in pegfilgrastim?
- How do you increase white blood cells during chemo?
- How many biosimilars have been approved in the United States?
- When does Neulasta reach peak levels?
- How long do the side effects of the Neulasta (pegfilgrastim) shot last?